CA2511269A1 — Multimarker panel based on p1gf for diabetes type 1 and 2

USPTO Abstract

The present invention relates to a methods and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one angiogenesis marker or a variant thereof in a sample from the patient, (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or the risk. The present invention also relates to combining the measurement of markers comprising angiogenesis markers, cardiac hormones, natriuretic peptides, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PlGF, and sCD40L.